Company / Total Assets
Acadia Pharmaceuticals Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$1.6B
FY2025
5-year range
$587.8M / $1.6B
FY2021-FY2025
Trend
+31.7%
vs FY2024
Sector context
#50 of 214
Health Care
What the data says
Acadia Pharmaceuticals's total assets of $1.6B is higher than 77% of companies in the Health Care sector (FY2025). Total Assets has increased for 3 consecutive years, from $588M in FY2022 to $1.6B in FY2025.
Based on SEC 10-K filings.
$1.6B in FY2025 with a 5-year CAGR of +14.9%. Top quartile in the Health Care sector.
Improved from $749M to $1.6B over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- +38.6%
- 5-Year CAGR
- +14.9%
- 10-Year CAGR
- -
Sector benchmark
Top 23% in Health CareTop 23% of 214This company $1.6B Sector average $7.5B
▼
-79.1% below sector average
Key checks
Key Insights
- Acadia Pharmaceuticals's total assets has grown for 3 consecutive years.
- 5-year CAGR of +14.9%, indicating consistent growth.
- In FY2025, total assets increased 31.7% year-over-year.
- Ranks #50 out of 214 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.6B | +31.7% |
| FY2024 | $1.2B | +58.6% |
| FY2023 | $749.0M | +27.4% |
| FY2022 | $587.8M | -16.0% |
| FY2021 | $700.1M | -10.5% |
| FY2020 | $782.6M | -0.1% |
| FY2019 | $783.2M | +45.0% |
| FY2018 | $540.2M | +40.5% |
| FY2017 | $384.5M | -31.5% |
| FY2016 | $561.2M | +152.9% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026